NICE Decision On Arthritis Opens Door For Biosimilars In England
UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules
Executive Summary
A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.